| 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | | --- | --- | --- | | 即将召开： | | | | 2025年6月12日，首届全球医美科技大会 | | | | 2025年7月17日，第二届全球医疗科技大会 | | | | 2025年9月4-5日，第三届全球手术机器人大会 | | | 近日， 上海心光生物医药有限责任公司 （以下简称"心光生物"）宣布完成 Pre-A++轮融资 ，本轮融资由兴富资本投资，印时资本担任财务顾问。这是心光生物在 过去12个月内完成的 第三笔融资 。本轮募集的资金将主要用于加速其自主研发的便携式透析机的量产及注册取证。 # 关于 心光生物 心光生物 成立于2018年9月，总部位于上海，是一家专注于透析技术的创新型高科技医疗器械企业。公司由创始人李祥海先生在复旦大学读博期间创立。心光生物 的主营业务是开发和提供家庭血液透析解决方案，包括 透析耗材、血管介入以及便携式透析机 的整体解决方案。公司成功掌握了将酶用于血液净化领域的高壁垒 核心技术，并围绕家庭透析逐步形成了完整的产品线。 心光生物的核心技术是 透析液再生技术 ，该技 ...

Core Insights - Shanghai Xinguang Biomedical Co., Ltd. has completed a Pre-A++ financing round led by Xingfu Capital, marking its third financing in the past 12 months [1] - The funds will primarily be used to accelerate the mass production and registration of its portable dialysis machine [1] - The company aims to innovate in the dialysis field and establish a domestic technological barrier in China [2] Company Overview - Founded in 2018 at Fudan Science Park, the company focuses on making dialysis technology more accessible for over three million uremic patients globally [1] - The company emphasizes the need for disruptive innovation in the dialysis sector, particularly in the context of China's medical device industry [2] Industry Context - As of 2023, the total number of dialysis patients in China has exceeded 1.06 million, with an annual increase of 185,000 patients, reflecting a stable compound annual growth rate of 12% to 14% [1] - The dialysis industry faces challenges from centralized procurement policies that limit profit margins and the development of "Me too" products [2][3] - The company has achieved significant breakthroughs in large animal model experiments, gaining recognition from leading medical experts and investment institutions [3] Future Prospects - The company is working on a home dialysis solution that is cost-effective and improves dialysis adequacy through a dialysis fluid regeneration scheme [3] - Future plans include remote intelligent monitoring of the entire dialysis process and patient vital sign data monitoring, aiming to provide comprehensive treatment and follow-up management for end-stage renal disease patients [3]